Background Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are currently used to treat patients with diabetes. Previous studies have demonstrated that treatment with SGLT-2 inhibitors is accompanied by altered metabolic phenotypes. However. it has not been investigated whether the hypothalamic circuit participates in the development of the compensatory metabolic phenotypes triggere... https://www.pomyslnaszycie.com/western-321-cyl-reg-adaptor-cga-200-to-cga-510-online-sale/